TCS 46B manufacturers
- TCS 46b
-
- $39.00
-
2026-07-27
- CAS:302799-86-6
- Purity: 99.81%
- Supply Ability: 10g
|
| | TCS 46B Basic information |
| Product Name: | TCS 46B | | Synonyms: | TCS 46B;1,3-Dihydro-5-[3-[4-(phenylmethyl)-1-2H-benzimidazol-2-one;2H-Benzimidazol-2-one, 1,3-dihydro-5-[3-[4-(phenylmethyl)-1-piperidinyl]-1-propyn-1-yl]-;5-(3-(4-benzylpiperidin-1-yl)prop-1-yn-1-yl)-1H-benzo[d]imidazol-2(3H)-one;5-(3-(4-Benzylpiperidin-1-yl)prop-1-yn-1-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one | | CAS: | 302799-86-6 | | MF: | C22H23N3O | | MW: | 345.44 | | EINECS: | | | Product Categories: | | | Mol File: | 302799-86-6.mol |  |
| | TCS 46B Chemical Properties |
| Boiling point | 440.4±38.0 °C(Predicted) | | density | 1.24±0.1 g/cm3(Predicted) | | storage temp. | Store at RT | | solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol | | form | Powder | | pka | 11.51±0.30(Predicted) | | color | Off-white to light yellow |
| | TCS 46B Usage And Synthesis |
| Uses | TCS 46b is a subtype-selective NR1A/NR2B NMDA receptor antagonist. | | Biological Activity | Orally active, subtype-selective NR1A/NR2B NMDA receptor antagonist (IC 50 values are 5.3, 35000 and > 100000 nM for NR1A/2B, NR1A/2A and NR1A/2C receptor subtypes respectively). Potentiates the effect of L-DOPA in 6-OHDA-lesioned rats following oral administration. | | in vivo | TCS 46b (Compound 46b; 10 and 30 mg/kg; p.o. or i.p.; once) potentiates the effects of L-DOPA in the 6-OHDA-lesioned rat[1]. | Animal Model: | SpragueDawley rats, 6-hydroxydopamine-lesioned (6-OHDA) rat model[1] | | Dosage: | 10 and 30 mg/kg | | Administration: | PO or IP, once | | Result: | Showed significant potentiation of the effects of L-DOPA in this model. |
|
| | TCS 46B Preparation Products And Raw materials |
|